Announcements Trials
Browse Landscape

Phase

Phase 1 28Phase 2 25Phase 3 8Phase 1/2 5Phase 4 2Phase 2/3 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Tumor-Agnostic 1

Conditions

Melanoma 2Skin Neoplasms 1

Interventions

Imiquimod 15Aminolevulinic Acid 8Fluorouracil 6Diclofenac 63-ingenyl angelate 6Nivolumab 5Cryotherapy 5tirbanibulin 4methyl 5-aminolevulinate 4Sirolimus 4denileukin diftitox 3aldesleukin 3Photochemotherapy 3Ipilimumab 3Blood Specimen Collection 3relatlimab 2Vemurafenib 2Tacrolimus 2Prednisone 2Ointments 2Methotrexate 2Immune Checkpoint Inhibitors 2HhAntag691 2Gels 2Cyclosporine 2Cryosurgery 2trametinib 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1technetium Tc 99m nanocolloid 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Vemurafenib × Dermatologic × Clear all
NCT01683188 2021-02-01

PROCLIVITY01

Clinigen, Inc.

Phase 4 Terminated
53 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT01898585 2020-01-07

An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma

Hoffmann-La Roche

Phase 4 Completed
60 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡